[KR-바이오] 07/30 Korea Market Insights

As a senior equity analyst, I evaluate Samsung Biologics’ acquisition of (Polypeptide Group) for approximately KRW 2.7 trillion as a highly strategic and transformative move. This landmark (M&A)—the largest in the history of the Korean biotech industry—enables the company to successfully expand its (CDMO) portfolio into high-growth (peptide therapeutics), capturing surging global demand for next-generation (obesity treatments). Combined with ongoing infrastructure expansion like the Songdo 3rd Campus, this acquisition significantly strengthens Samsung Biologics’ long-term valuation and market dominance.

As a senior equity analyst, I evaluate **Celltrion**’s recent news flow as fundamentally favorable, driven by strong financial performance and strategic pipeline expansion.

Despite competitive pressures in certain areas—such as Samsung Bioepis releasing Phase 3 data for a Keytruda biosimilar—Celltrion demonstrates robust growth momentum. The company recently reported a (second-quarter earnings surprise), underscoring its solid operational execution. Furthermore, the firm is successfully broadening its global footprint, capturing substantial (market share in Europe) and securing favorable (insurance coverage in the US) for its flagship biosimilars.

Beyond its core biosimilar business, future valuation upside is supported by diversification into next-generation therapeutics, including the targeted disclosure of (obesity treatment preclinical results) within the year and steady progress in (anticancer ADC development). Trading at levels (significantly undervalued compared to peers), the stock offers an attractive entry point for long-term investors.

As a senior equity analyst, the most critical corporate action among the news headlines is Yuhan Corporation’s massive treasury stock retirement.

Yuhan Corporation has announced a definitive decision to retire the entirety of its treasury shares, amounting to approximately 425.3 billion KRW. This aggressive move directly addresses chronic undervaluation issues by significantly enhancing shareholder value and improving Earnings Per Share (EPS). Unlike temporary stock buybacks, a full-scale retirement signals strong management confidence in future cash flows and long-term fundamental growth, particularly driven by its flagship oncology pipeline (Leclaza) and strategic investments in biotech innovators like Progen. This structurally shifts the company’s valuation multiple upward by prioritizing shareholder returns.

As a senior equity analyst, I evaluate the recent developments surrounding Alteogen as fundamentally positive for the company’s medium-to-long-term valuation.

First, the effective resolution of the (patent dispute) removes a major overhang that previously caused significant market volatility and valuation compression. This legal clarity paves the way for a smoother global commercialization of its subcutaneous (SC) formulation technologies, spearheaded by partnerships like MSD’s (Keytruda SC).

Second, the management’s strategic decision to defer the (KOSPI transfer) in favor of a (30% bonus issue) (free capital increase) is a shareholder-friendly move. While maintaining its dominant market leadership position on the KOSPI-rivaling KOSDAQ index, the bonus issue enhances stock liquidity and rewards loyal retail and institutional investors, strengthening market confidence ahead of upcoming pipeline catalysts.

As a senior equity analyst, I evaluate the recent developments surrounding HLB as a major inflection point for the company. The resolution of critical regulatory hurdles regarding its (liver cancer new drug) and the successful submission of the corrective action plan for the (FDA manufacturing site) significantly revive expectations for commercialization. These milestones have alleviated primary market overhangs, driving strong investor sentiment and a notable rebound in the (stock price). While execution risks regarding the final regulatory review remain, the removal of major substantive deficiencies marks a critical step forward for HLB’s global expansion.